About this data
Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.
Siltuximab
- Company
- Memorial Sloan Kettering Cancer Center
- Mechanism
- Mechanism not yet reported
- Route
- Route not yet reported
- Recruiting trials
- 8 recruiting
Efficacy results: Not yet reported
8 recruiting studies currently listed on ClinicalTrials.gov.
Data source: ClinicalTrials.gov · trial data as of Nov 6, 2026
Find a Clinical Trial Near Me
See recruiting studies for Siltuximab and check eligibility with the study team.
Trial details
-
Recruiting NCT NCT05684692
Screening Trial for Pain Relief in Schwannomatosis (STARFISH)
Not yet reported Massachusetts General Hospital 40 participants Est. completion 2028-11-30 1 site Stand-aloneOther conditions: Schwannomatosis, Schwannomas, Pain, ChronicView official trial listing → -
Recruiting NCT NCT06447376
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
Not yet reported Taylor Brooks 20 participants Est. completion 2028-09-01 1 site Stand-aloneOther conditions: Non-Hodgkin Lymphoma, Cytokine Release SyndromeView official trial listing → -
Recruiting NCT NCT06470971
Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial
Not yet reported Yuanquan Yang 40 participants Est. completion 2030-12-31 1 site Stand-aloneOther conditions: Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System NeoplasmView official trial listing → -
Recruiting NCT NCT06679829
A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
Not yet reported Memorial Sloan Kettering Cancer Center 215 participants Est. completion 2027-11 7 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Recruiting NCT NCT06990711
A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung Transplantation
Not yet reported Washington University School of Medicine 30 participants Est. completion 2028-08-31 2 sites Stand-aloneOther conditions: Antibody Mediated Rejection of Lung TransplantView official trial listing → -
Recruiting NCT NCT07106671
A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma
Not yet reported Institute of Hematology & Blood Diseases Hospital, China 20 participants Est. completion 2027-08-01 1 site Stand-aloneOther conditions: CRS - Cytokine Release Syndrome, MyelomaView official trial listing → -
Recruiting NCT NCT07570173
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
Not yet reported, Not yet reported Merck Sharp & Dohme LLC 340 participants Est. completion 2033-10-18 28 sites Stand-aloneOther conditions: B-cell Acute Lymphoblastic LeukemiaView official trial listing → -
Recruiting NCT NCT07709000
A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)
Not yet reported Merck Sharp & Dohme LLC 60 participants Est. completion 2033-11-16 7 sites Stand-aloneOther conditions: Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Hematologic MalignanciesView official trial listing → -
Completed NCT NCT00265135
A Study of CNTO 328 in Subjects With Metastatic Renal Cell Carcinoma
Not yet reported, Not yet reported Centocor, Inc. 68 participants Est. completion 2006-02 14 sitesOther conditions: Carcinoma, Renal CellView official trial listing → -
Withdrawn NCT NCT00311545
S0351, CNTO 328 in Treating Patients With Unresectable or Metastatic Kidney Cancer
Not yet reported SWOG Cancer Research NetworkOther conditions: Kidney CancerView official trial listing → -
Terminated NCT NCT00385827
A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)
Not yet reported Centocor, Inc. 106 participants Est. completion 2008-11 34 sites Stand-aloneOther conditions: Cancer, ProstateView official trial listing → -
Completed NCT NCT00401765
A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer
Not yet reported Centocor, Inc. 40 participants Est. completion 2009-11 5 sitesOther conditions: Prostatic NeoplasmsView official trial listing → -
Completed NCT NCT00401843
A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma
Not yet reported Janssen Research & Development, LLC 307 participants Est. completion 2019-09-24 80 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT00402181
An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma
Not yet reported Centocor, Inc. 53 participants Est. completion 2009-07 13 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT00412321
A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease
Not yet reported Centocor, Inc. 67 participants Est. completion 2011-04 9 sitesOther conditions: Lymphoma, Non-Hodgkin, Multiple Myeloma, Giant Lymph Node HyperplasiaView official trial listing → -
Completed NCT NCT00433446
S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
Not yet reported SWOG Cancer Research Network 62 participants Est. completion 2011-07 123 sitesOther conditions: Prostate CancerView official trial listing → -
Completed NCT NCT00841191
A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors
Not yet reported, Not yet reported Centocor, Inc. 84 participants Est. completion 2011-04 12 sites Stand-aloneOther conditions: Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Head and Neck Neoplasms, Lung NeoplasmsView official trial listing → -
Completed NCT NCT00911859
A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients
Not yet reported Janssen Research & Development, LLC 118 participants Est. completion 2013-04 37 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT01024036
A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease
Not yet reported Janssen Research & Development, LLC 79 participants Est. completion 2017-02-24 56 sites Stand-aloneOther conditions: Multicentric Castleman's DiseaseView official trial listing → -
Completed NCT NCT01219010
A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma
Not yet reported Janssen Research & Development, LLC 30 participants Est. completion 2014-03 8 sites Stand-aloneOther conditions: Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Plasma Cell NeoplasmView official trial listing → -
Withdrawn NCT NCT01266811
A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Not yet reported Centocor, Inc. Est. completion 2014-12 48 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Terminated NCT NCT01309412
A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma
Not yet reported Janssen Pharmaceutical K.K. 9 participants Est. completion 2012-12 5 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT01400503
A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease
Not yet reported Janssen Research & Development, LLC 60 participants Est. completion 2017-03-01 26 sites Stand-aloneOther conditions: Multicentric Castleman's DiseaseView official trial listing → -
Completed NCT NCT01484275
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Not yet reported Janssen Research & Development, LLC 85 participants Est. completion 2019-08-21 40 sites Stand-aloneOther conditions: High-risk Smoldering Multiple MyelomaView official trial listing → -
Terminated NCT NCT01513317
A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome
Not yet reported Janssen Research & Development, LLC 76 participants Est. completion 2012-09 23 sites Stand-aloneOther conditions: Myelodysplastic SyndromeView official trial listing → -
Completed NCT NCT01531998
Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)
Not yet reported, Not yet reported M.D. Anderson Cancer Center 14 participants Est. completion 2014-05 1 site Stand-aloneOther conditions: MyelomaView official trial listing → -
Completed NCT NCT02074800
A Study to Assess the Safety and Pharmacokinetics of a Single Intravenous Administration of CNTO 328 Derived From 2 Different Cell Lines in Healthy Participants
Not yet reported Centocor, Inc. 145 participants Est. completion 2009-06 2 sitesOther conditions: HealthyView official trial listing → -
Completed NCT NCT02641522
Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes
Not yet reported Carla Greenbaum, MD 10 participants Est. completion 2017-03-16 1 site Stand-aloneOther conditions: Type 1 DiabetesView official trial listing → -
Status unknown NCT NCT02796859
Siltuximab in Schizophrenia
Not yet reported, Not yet reported Brian Miller 30 participants Est. completion 2023-12-31 1 siteOther conditions: Schizophrenia, Psychotic DisordersView official trial listing → -
Withdrawn NCT NCT02805868
Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis
Not yet reported Northwestern University Stand-aloneOther conditions: Myelofibrosis, Polycythemia Vera, Primary Myelofibrosis, ThrombocytopeniaView official trial listing → -
Active, not recruiting NCT NCT03315026
Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis
Not yet reported Memorial Sloan Kettering Cancer Center 30 participants Est. completion 2027-10 1 site Stand-aloneOther conditions: Multiple Myeloma, AL AmyloidosisView official trial listing → -
Completed NCT NCT04191421
Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer
Not yet reported, Not yet reported Emory University 35 participants Est. completion 2023-04-05 3 sites Stand-aloneOther conditions: Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8View official trial listing → -
Completed NCT NCT04322188
An Observational Study of the Use of Siltuximab (SYLVANT) in Patients Diagnosed With COVID-19 Infection Who Have Developed Serious Respiratory Complications
A.O. Ospedale Papa Giovanni XXIII 220 participants Est. completion 2020-05-08 1 siteOther conditions: Severe Acute Respiratory Syndrome (ARDS) Secondary to SARS-COV-2 InfectionView official trial listing → -
Completed NCT NCT04329650
Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia
Not yet reported Judit Pich Martínez 163 participants Est. completion 2021-02-26 4 sites Stand-aloneOther conditions: COVID-19View official trial listing → -
Completed NCT NCT04330638
Treatment of COVID-19 Patients With Anti-interleukin Drugs
Not yet reported University Hospital, Ghent 342 participants Est. completion 2021-05-21 15 sitesOther conditions: COVID-19View official trial listing → -
Status unknown NCT NCT04486521
Anti-IL6 and Corticosteroid Monotherapy vs Combination in COVID-19
King Faisal Specialist Hospital & Research Center 860 participants Est. completion 2021-07-22 1 siteOther conditions: Critical Illness, Corona Virus Infection, Cytokine Release SyndromeView official trial listing → -
Terminated NCT NCT04616586
SILtuximab in Viral ARds (SILVAR) Study
Not yet reported RECORDATI GROUP 555 participants Est. completion 2021-04-01 2 sites Stand-aloneOther conditions: Acute Respiratory Distress Syndrome, Lung Diseases, Pneumonia, Respiratory Tract Infections, Respiratory Tract DiseaseView official trial listing → -
Terminated NCT NCT04838860
Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease
Not yet reported RECORDATI GROUP 22 participants Est. completion 2021-04-01 1 siteOther conditions: Idiopathic Multicentric Castleman's DiseaseView official trial listing → -
Withdrawn NCT NCT04850443
Treatment of IL-6 and Its Receptor Antagonists in Children's Severe Sepsis.
Children's Hospital of Fudan University Est. completion 2024-12-31Other conditions: Critical Illness Sepsis, SevereView official trial listing → -
Completed NCT NCT04975555
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
Not yet reported University of Alabama at Birmingham 20 participants Est. completion 2026-01-20 1 site Stand-aloneOther conditions: Cytokine Release Syndrome, ICANS, Lymphoma, Non-Hodgkin, Multiple Myeloma, Acute Lymphoblastic LeukemiaView official trial listing → -
Terminated NCT NCT05316116
Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)
Not yet reported H. Lee Moffitt Cancer Center and Research Institute 6 participants Est. completion 2024-10-18 1 site Stand-aloneOther conditions: Large Granular Lymphocyte LeukemiaView official trial listing → -
Completed NCT NCT05665725
Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma
Not yet reported Timothy Voorhees 11 participants Est. completion 2024-09-06 1 site Stand-aloneOther conditions: Non-Hodgkin LymphomaView official trial listing → -
Status unknown NCT NCT05697510
Dose-escalation of Siltuximab in Combination With Idarubicin and Cytarabine Chemotherapy in Patients With Acute Myeloblastic Leukaemia (AML) With Poor Prognosis: SILTUXILAM
Not yet reported Nantes University Hospital 12 participants Est. completion 2025-06-30 1 site Stand-aloneOther conditions: Acute Myeloid Leukemia (AML)View official trial listing → -
Withdrawn NCT NCT06352866
Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM
Not yet reported Jack Khouri, MD Est. completion 2025-12-01 1 site Stand-aloneOther conditions: Multiple Myeloma, Cytokine Release Syndrome, Refractory Multiple Myeloma, Immune Effector Cell Associated Neurotoxicity SyndromeView official trial listing → -
Status unknown NCT NCT06720870
An Italian Multicenter Retrospective Observational Study to Assess Effectiveness and Safety of Siltuximab for Patients with Castleman's Disease Treated in Italy in a Real-life Context
IRCCS Azienda Ospedaliero-Universitaria di Bologna 65 participants Est. completion 2025-01 12 sitesOther conditions: Castleman DiseaseView official trial listing → -
Not yet recruiting NCT NCT07870278
A Clinical Trial of MK-6255 to Treat Endometrial and Ovarian Cancer (MK-6255-001)
Not yet reported Merck Sharp & Dohme LLC 80 participants Est. completion 2031-07-07 Stand-aloneOther conditions: Ovarian Neoplasms, Endometrial NeoplasmsView official trial listing → -
Not yet recruiting NCT NCT07908537
A Clinical Trial of Gocatamig (MK-6070) With Durvalumab in Participants With Small Cell Lung Cancer (MK-6070-004)
Not yet reported Merck Sharp & Dohme LLC 564 participants Est. completion 2036-03-10 Stand-aloneOther conditions: Small Cell Lung CancerView official trial listing →
Efficacy history
Not yet reported.
Safety
Not yet reported.
Sources
Also known as: Siltuximab, Sylvant
Related On The Pen coverage
No related coverage yet.
This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.